Alterity Therapeutics Reports Strong Cash Flow and Advancements
Highlights
- Positive topline data reported for ATH434-201 Phase 2 clinical trial focusing on Multiple System Atrophy (MSA)
- Data presented at a significant medical conference spotlighting ATH434's potential
- Completion of ATH434-202 open-label trial for advanced MSA
- Strong cash position of A$17.96M with additional funds raised
MELBOURNE, Australia, and SAN FRANCISCO — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), a leader in biotechnology committed to addressing neurodegenerative diseases, recently shared its quarterly cash flow report for the third quarter of fiscal year 2025, covering activities up to March 31, 2025.
David Stamler, M.D., the CEO of Alterity, expressed his excitement about the company’s progress. "This fiscal quarter has been a remarkable period for Alterity Therapeutics. The impressive results from our ATH434 Phase 2 double-blind trial emphasize its promise as a disease-modifying treatment for MSA, attracting attention from the medical community. Currently, there are no approved therapies for MSA, and we believe ATH434 could transform treatment options for patients."
Stamler added, "Completing our open-label Phase 2 trial in patients with more advanced MSA marks a significant milestone. Data from this trial are anticipated midway through the year, providing critical insights into ATH434's potential benefits for patients in serious health conditions. We eagerly anticipate discussions with the U.S. Food and Drug Administration and European regulatory agencies to further advance ATH434's development."
At the end of March, Alterity reported a cash balance of A$17.96M, with operating cash outflows for the quarter recorded at A$0.73M. The company disclosed that related party payments of A$80K included directors' fees and other remunerations at market rates as per ASX Listing Rule 4.7C.
Clinical Progress with ATH434
ATH434–201: Phase 2 Clinical Trial Insights
On January 30, 2025, Alterity revealed positive topline results from ATH434-201, showcasing significant clinical efficacy. Following the quarter, further data was presented on April 10, 2025, during an oral session at the American Academy of Neurology's annual meeting. This supports continued progress for ATH434 in treating MSA.
The ATH434-201 trial involved a randomized, double-blind, placebo-controlled design, assessing ATH434 among individuals with MSA. The study not only tracked therapy efficacy and biomarkers but also captured data on patients' outpatient activity through wearable sensors. Ultimately, 77 participants received either ATH434 or a placebo over a span of 12 months.
Analysis revealed that 71 patients met the clinical endpoint of having a post-baseline assessment with the modified Unified Multiple System Atrophy Rating Scale (UMSARS). ATH434 demonstrated a meaningful reduction in disease severity compared to placebo, showing a 48% relative treatment effect at the 50 mg dose and a 30% effect at 75 mg after 52 weeks. Other evaluations indicated statistically significant improvements in multiple measures, demonstrating ATH434's potential in enhancing patients' quality of life.
Detailed Efficacy Findings
Improvements in treatment groups were consistent in various assessments. For instance, patient-reported outcomes on orthostatic hypotension symptoms showed that participants receiving ATH434 experienced benefits compared to quienes who received placebos. In addition, robust engagement was established through wearable device data, indicating increased step counts and walking durations in those treated with ATH434.
Advancements with ATH434–202
Open-label Phase 2 Clinical Trial Developments
On March 27, 2025, Alterity announced the completion of the final patient visit in the ATH434-202 Phase 2 study, aimed at evaluating safety, efficacy, and biomarker engagement in participants with advanced MSA. This trial enables the company to further explore ATH434’s impacts within a more severely affected patient demographic versus those in ATH434-201.
Topline data from this open-label study is anticipated later in 2025, providing pivotal information to guide Alterity's development direction for MSA treatment.
Corporate and Financial Developments
Throughout the reporting period, Alterity fortified its financial health, raising approximately A$15.0M through various financing deals. After the quarter ended, an additional A$27.1M was secured through the completion of a two-tranche placement. Moreover, Alterity successfully obtained a tax refund of $1.65M from the Australian Taxation Office under the Research and Development Tax Incentive Program for qualifying activities conducted in prior fiscal years.
These funds positioned Alterity to expedite regulatory and development efforts for ATH434 and to continue pursuing novel compounds targeting disorders, including Parkinson’s disease.
About Alterity Therapeutics Limited
Alterity Therapeutics is focused on pioneering alternative futures for individuals grappling with neurodegenerative diseases. The company’s primary emphasis is developing disease-modifying therapies in Parkinson’s disease and related conditions. Recently, ATH434 has shown promising results in clinical trials addressing MSA, a rapidly progressing condition related to Parkinson’s. Alongside this, Alterity boasts a diverse drug discovery platform aimed at generating new pharmacological strategies for treating serious neurological conditions.
For further inquiries, visit the Company’s website at www.alteritytherapeutics.com.
Frequently Asked Questions
What is the main focus of Alterity Therapeutics?
Alterity Therapeutics specializes in developing innovative treatments for neurodegenerative diseases, specifically targeting conditions like MSA and Parkinson's disease.
How is ATH434 showing promise in treating MSA?
The clinical trial data indicates that ATH434 may reduce disease severity and improve patient symptoms based on significant outcomes from the Phase 2 trials.
What financial steps has Alterity taken recently?
Alterity has strengthened its cash position by raising A$15.0M through financing and an additional A$27.1M post-quarter, along with a tax refund of $1.65M from the Australian government.
When can we expect data from the ATH434-202 trial?
Topline data from the ATH434-202 open-label trial is expected to be reported in mid-2025, representing critical insights for advanced MSA patients.
Where can I find more information about the company?
Additional information can be accessed through their official website at www.alteritytherapeutics.com.
